Allergan files lawsuit against government ban on off-label drug marketing

Allergan, maker of Botox, said it filed a free speech lawsuit against the Food and Drug Administration and Justice Department, charging that off-label marketing...

Allergan, maker of Botox, said it filed a free speech lawsuit against the Food and Drug Administration and Justice Department, charging that off-label marketing restrictions violated the First Amendment.

Specifically, the pharmaceutical company is questioning the federal government's ban on companies marketing off-label uses for drugs to physicians. Allergan is testing Botox, a wrinkle reducer, for treatment of migraines and upper limb spasticity in stroke victims.

Dow Jones writes:
Nonetheless, the case's outcome could have implications for the broader drug industry. If Allergan were to prevail, drug companies inclined to push the envelope on off-label marketing may feel emboldened. If Allergan loses, the status quo would be maintained.

BusinessWeek called it an "unprecedented lawsuit."

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.